This afternoon we watched Novo Nordisk A/S drop -7.8% to a price of $119.99 per share. The Large-Cap Pharmaceutical company is now trading -20.02% below its average target price of $150.03. Analysts have set target prices ranging from $82.48 to $169.95 per share for Novo Nordisk A/S, and have given the stock an average rating of buy.
The stock has a very low short interest at 0.1%, and a short ratio of 0.83. At 0.0%, the company's rate of insider ownership does not indicate that management is heavily invested in the corporation. Finally, we also note that a very small number of institutional investors are invested in the stock, with 9.8% of Novo Nordisk A/S's shares being owned by this investor type.
Institutions Invested in Novo Nordisk A/S
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-06-30 | Jennison Associates LLC | 1% | 21,220,641 | $2,546,349,666 |
| 2024-03-31 | FMR, LLC | 1% | 17,604,322 | $2,112,413,072 |
| 2024-03-31 | Fisher Asset Management, LLC | 0% | 13,724,718 | $1,646,883,856 |
| 2024-03-31 | Bank of America Corporation | 0% | 13,053,731 | $1,566,369,440 |
| 2024-03-31 | Sarofim, Fayez & Co | 0% | 11,815,837 | $1,417,829,583 |
| 2024-03-31 | Morgan Stanley | 0% | 12,011,853 | $1,441,350,328 |
| 2024-03-31 | Renaissance Technologies, LLC | 0% | 10,786,074 | $1,294,264,199 |
| 2024-03-31 | Folketrygdfondet | 0% | 8,756,034 | $1,050,671,572 |
| 2024-03-31 | Loomis Sayles & Company, LP | 0% | 8,852,532 | $1,062,250,753 |
| 2024-03-31 | Price (T.Rowe) Associates Inc | 0% | 8,589,222 | $1,030,655,132 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Novo Nordisk A/S.
